サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：結核治療薬市場：疾患タイプ別、治療タイプ別、流通チャネル別：世界の機会分析と産業予測、2021-2031年
市場調査レポート
商品コード
1298248

結核治療薬市場：疾患タイプ別、治療タイプ別、流通チャネル別：世界の機会分析と産業予測、2021-2031年

Tuberculosis Treatment Drugs Market By Disease Type, By Therapy Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 322 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
結核治療薬市場：疾患タイプ別、治療タイプ別、流通チャネル別：世界の機会分析と産業予測、2021-2031年
出版日: 2023年03月01日
発行: Allied Market Research
ページ情報: 英文 322 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

結核治療薬市場は2021年に19億2,996万米ドルと評価され、2031年には32億4,390万米ドルに達すると推定され、2022年から2031年までのCAGRは5.3%です。

結核は、結核菌によって引き起こされる感染症です。結核は主に肺に感染するが、腎臓、骨、脳など体の他の部位に感染することもあります。結核は、感染者が咳をしたり、くしゃみをしたり、話したりすることで空気感染します。結核は空気感染する病気であり、感染した飛沫を吸い込むことで人から人へと容易に感染します。結核の診断は通常、病歴、身体診察、胸部X線検査、喀痰顕微鏡検査や培養検査などの臨床検査の組み合わせに基づいて行われます。さらに、イソニアジド、リファンピン、エタンブトールなどの第一選択薬や、シクロステリン、エチオアミド、カプレオマイシンなどの第二選択薬が認可され、結核治療に使用されています。

結核治療薬市場を牽引する要因は、結核患者の増加です。例えば、米国疾病予防管理センター（CDC）の2022年の報告によると、2021年には結核患者が78億8,200万人、すなわち9.4％増加したとされています。このように、結核患者の増加は、市場成長を促進すると予想される薬剤に対する高い需要をもたらします。さらに、今後数年間で規制当局の承認を受けると予想される結核治療薬のパイプラインの増加が、予測期間中の成長を促進します。

さらに、さまざまなプログラムやキャンペーンを通じて、結核疾患や利用可能な治療法に関する患者の認知度を高めるための非政府組織や政府組織によるイニシアチブの増加は、市場の成長を後押しすると予測されます。加えて、結核を診断するための先端技術の採用や早期診断の重要性に関する認識の高まりが、市場の成長を後押しすると予測されます。さらに、多くの主要企業が、世界の結核治療薬市場における存在感を高めるために、提携、合意、アライアンスなどの主要戦略を採用しており、これが市場の成長を促進すると予想されます。

しかし、結核治療薬に伴う主な副作用などの要因が、結核治療薬市場の成長を抑制する可能性があります。また、広範な薬剤耐性の増加は市場の成長を妨げる可能性があります。

さらに、結核治療のための新規治療薬に対する需要の増加や、新規治療薬に対する規制承認の増加とともにパイプライン分子の強力な存在は、市場の主要プレーヤーに有利な機会を提供すると期待されています。

世界の結核治療薬市場は、疾患タイプ、治療タイプ、流通チャネル、地域に区分されます。疾患タイプ別では、市場は活動性結核と潜在性結核に分類されます。治療タイプ別では、市場はファーストライン治療とセカンドライン治療に分類されます。流通チャネル別では、市場は病院薬局、ドラッグストア＆小売薬局、オンラインプロバイダーに分類されます。地域別では、市場は北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋（日本、中国、インド、その他アジア太平洋地域）、ラテンアメリカ（中南米、中東・アフリカ）で分析されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競合の激しさ
  • 市場力学
    • 促進要因
      • 結核治療薬の研究開発の増加
      • 結核啓発のための政府機関のイニシアティブの高まり
      • 併用療法の採用増加
    • 抑制要因
      • 抗結核薬の副作用
      • 製品承認のための厳しい規制ガイドライン
    • 事業機会
      • 新興市場における成長機会
  • COVID-19の市場への影響分析

第4章 結核治療薬市場：疾患タイプ別

  • 概要
    • 市場規模および予測
  • 活動性結核
    • 主要市場動向、成長要因、機会
    • 市場規模および予測：地域別
    • 市場シェア分析：国別
  • 潜在性結核
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析： 国別

第5章 結核治療薬市場：治療タイプ別

  • 概要
    • 市場規模および予測
  • ファーストライン治療
    • 主要市場動向、成長要因、機会
    • 市場規模および予測：地域別
    • 市場シェア分析：国別
  • セカンドライン治療
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析： 国別

第6章 結核治療薬市場：流通チャネル別

  • 概要
    • 市場規模および予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • ドラッグストアと小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • オンラインプロバイダー
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析： 国別

第7章 結核治療薬市場：地域別

  • 概要
    • 市場規模・予測： 地域別
  • 北米
    • 主要動向と機会
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：治療タイプ別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 米国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • カナダ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • メキシコ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
  • 欧州
    • 主要動向と機会
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：治療タイプ別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ドイツ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • フランス
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • 英国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • イタリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • スペイン
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • その他欧州
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
  • アジア太平洋地域
    • 主要動向と機会
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：治療タイプ別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 日本
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • 中国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • インド
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • その他アジア太平洋地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
  • ラテンアメリカ・中東・アフリカ
    • 主要動向と機会
    • 市場規模・予測：疾患タイプ別
    • 市場規模・予測：治療タイプ別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ラテンアメリカ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別
      • 中東・アフリカ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：疾患タイプ別
      • 市場規模・予測：治療タイプ別
      • 市場規模・予測：流通チャネル別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2021年

第9章 企業プロファイル

  • Lupin
  • Macleods Pharmaceuticals Ltd.
  • Sanofi
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • FRESENIUS SE & Co. KGaA（Fresenius Kabi）
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • ANI Pharmaceuticals, Inc.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 02. TUBERCULOSIS TREATMENT DRUGS MARKET FOR ACTIVE TUBERCULOSIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. TUBERCULOSIS TREATMENT DRUGS MARKET FOR LATENT TUBERCULOSIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 05. TUBERCULOSIS TREATMENT DRUGS MARKET FOR FIRST LINE THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. TUBERCULOSIS TREATMENT DRUGS MARKET FOR SECOND LINE THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 08. TUBERCULOSIS TREATMENT DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. TUBERCULOSIS TREATMENT DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. TUBERCULOSIS TREATMENT DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. TUBERCULOSIS TREATMENT DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 13. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 14. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 17. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 18. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 19. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 20. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 21. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 22. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 23. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 24. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 25. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 26. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 29. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 30. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 32. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 33. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 34. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 35. UK TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 36. UK TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 37. UK TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 38. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 39. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 40. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 41. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 42. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 43. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 45. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 46. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 48. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 49. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 51. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 52. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 53. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 54. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 55. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 56. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 58. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 59. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 60. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 61. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 62. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 63. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 64. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 65. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 67. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 68. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 69. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
  • TABLE 71. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
  • TABLE 72. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. LUPIN: KEY EXECUTIVES
  • TABLE 74. LUPIN: COMPANY SNAPSHOT
  • TABLE 75. LUPIN: PRODUCT SEGMENTS
  • TABLE 76. LUPIN: PRODUCT PORTFOLIO
  • TABLE 77. LUPIN: KEY STRATERGIES
  • TABLE 78. MACLEODS PHARMACEUTICALS LTD.: KEY EXECUTIVES
  • TABLE 79. MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • TABLE 80. MACLEODS PHARMACEUTICALS LTD.: PRODUCT SEGMENTS
  • TABLE 81. MACLEODS PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 82. SANOFI: KEY EXECUTIVES
  • TABLE 83. SANOFI: COMPANY SNAPSHOT
  • TABLE 84. SANOFI: PRODUCT SEGMENTS
  • TABLE 85. SANOFI: PRODUCT PORTFOLIO
  • TABLE 86. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 87. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 88. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
  • TABLE 89. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 90. OTSUKA PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
  • TABLE 91. PFIZER INC.: KEY EXECUTIVES
  • TABLE 92. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 93. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 94. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 95. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): KEY EXECUTIVES
  • TABLE 96. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): COMPANY SNAPSHOT
  • TABLE 97. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT SEGMENTS
  • TABLE 98. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT PORTFOLIO
  • TABLE 99. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 100. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 101. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 102. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 103. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 108. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 110. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 111. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 112. ANI PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 113. ANI PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 114. ANI PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 115. ANI PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 116. ANI PHARMACEUTICALS, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN TUBERCULOSIS TREATMENT DRUGS MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALTUBERCULOSIS TREATMENT DRUGS MARKET
  • FIGURE 10. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR ACTIVE TUBERCULOSIS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR LATENT TUBERCULOSIS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 13. TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR FIRST LINE THERAPY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR SECOND LINE THERAPY, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 16. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF TUBERCULOSIS TREATMENT DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 20. TUBERCULOSIS TREATMENT DRUGS MARKET BY REGION, 2021
  • FIGURE 21. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 22. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 23. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. UK TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 40. COMPETITIVE DASHBOARD
  • FIGURE 41. COMPETITIVE HEATMAP: TUBERCULOSIS TREATMENT DRUGS MARKET
  • FIGURE 42. TOP PLAYER POSITIONING, 2021
  • FIGURE 43. LUPIN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 45. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 47. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 48. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 50. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 52. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 53. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 54. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. ANI PHARMACEUTICALS, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 63. ANI PHARMACEUTICALS, INC.: REVENUE SHARE BY REGION, 2021 (%)
目次
Product Code: A13238

The Tuberculosis Treatment Drugs Market valued for $1,929.96 million in 2021 and is estimated to reach $3,243.90 million by 2031, exhibiting a CAGR of 5.3% from 2022 to 2031.

Tuberculosis Treatment Drugs Market - IMG1

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs, but can also affect other parts of the body such as the kidneys, bones, and brain. TB is transmitted through the air when an infected person coughs, sneezes, or talks. It is an airborne disease, which means that it can easily spread from person to person through the inhalation of infected droplets. The diagnosis of TB is typically based on a combination of medical history, physical examination, chest X-ray, and laboratory tests such as sputum microscopy and culture. Moreover, various first line drugs such as isoniazid, rifampin, ethambutol, and others and second line drugs such as cyclosterine, ethioamide, capreomycin, and others are approved and used to treat tuberculosis.

The driving factor for tuberculosis treatment drugs market is rise in prevalence of tuberculosis cases. For instance, according to report of Centers for Disease Control and Prevention (CDC) 2022, it was stated that 7,882 million cases of TB were reported in 2021, i.e. 9.4% increase in TB cases. Thus, rise in prevalence of tuberculosis cases results in high demand for drugs which is expected to drive the growth of market. Further, increase in number of pipeline medications for treating tuberculosis disease that is anticipated to receive regulatory approval in the upcoming years; will drive the growth during the forecast period.

Furthermore, rise in initiatives by non-government & government organizations to increase awareness about the TB disease and available treatments among the patients through different programs and campaigns is predicted to boost the growth of the market. In addition, rise in adoption of advanced technologies to diagnose tuberculosis disease and awareness about the importance of early diagnosis is anticipated to boost the market growth. Moreover, many key players have adopted key strategies such as collaboration, agreement, or alliance to increase their market presence in the global tuberculosis treatment drugs market, which is expected to drive the growth of the market.

However, factors such as major side effects associated with tuberculosis drugs may restrain the growth of tuberculosis treatment drugs market. In addition, increase in extensive drug resistance can hamper the growth of the market.

Moreover, rise in demand for novel therapeutics for treating tuberculosis and strong presence of pipeline molecules along with rise in regulatory approvals for new therapeutics is expected to offer lucrative opportunities to key players of market.

The global tuberculosis treatment drugs market is segmented into disease type, therapy type, distribution channel, and region. On the basis of disease type, the market is categorized into active tuberculosis and latent tuberculosis. As per therapy type, the market is categorized into first line therapy and second line therapy. According to distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).

Major key players that operate in the global tuberculosis treatment drugs market are: Lupin, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA (Fresenius Kabi), Johnson & Johnson, Teva Pharmaceuticals, Novartis AG, ANI Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., and Macleods Pharmaceuticals Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tuberculosis treatment drugs market analysis from 2021 to 2031 to identify the prevailing tuberculosis treatment drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the tuberculosis treatment drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global tuberculosis treatment drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Active Tuberculosis
  • Latent Tuberculosis

By Therapy Type

  • First Line Therapy
  • Second Line Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

  • Lupin
  • Sanofi
  • Pfizer Inc.
  • FRESENIUS SE & Co. KGaA (Fresenius Kabi)
  • Johnson & Johnson
  • Novartis AG
  • Macleods Pharmaceuticals Ltd.
  • ANI Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in R&D for tuberculosis drugs
      • 3.4.1.2. Growing initiatives from government organizations for tuberculosis awareness
      • 3.4.1.3. Rise in adoption of combinational therapy
    • 3.4.2. Restraints
      • 3.4.2.1. Adverse effects of Anti-Tuberculosis Drugs
      • 3.4.2.2. Stringent Regulatory Guidelines for product approval
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Active Tuberculosis
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Latent Tuberculosis
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. First Line Therapy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Second Line Therapy
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: TUBERCULOSIS TREATMENT DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Disease Type
    • 7.2.3. Market size and forecast, by Therapy Type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Disease Type
      • 7.2.5.1.3. Market size and forecast, by Therapy Type
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Disease Type
      • 7.2.5.2.3. Market size and forecast, by Therapy Type
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Disease Type
      • 7.2.5.3.3. Market size and forecast, by Therapy Type
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Disease Type
    • 7.3.3. Market size and forecast, by Therapy Type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Disease Type
      • 7.3.5.1.3. Market size and forecast, by Therapy Type
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Disease Type
      • 7.3.5.2.3. Market size and forecast, by Therapy Type
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Disease Type
      • 7.3.5.3.3. Market size and forecast, by Therapy Type
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Disease Type
      • 7.3.5.4.3. Market size and forecast, by Therapy Type
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Disease Type
      • 7.3.5.5.3. Market size and forecast, by Therapy Type
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Disease Type
      • 7.3.5.6.3. Market size and forecast, by Therapy Type
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Disease Type
    • 7.4.3. Market size and forecast, by Therapy Type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Disease Type
      • 7.4.5.1.3. Market size and forecast, by Therapy Type
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Disease Type
      • 7.4.5.2.3. Market size and forecast, by Therapy Type
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Disease Type
      • 7.4.5.3.3. Market size and forecast, by Therapy Type
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Rest of Asia-Pacific
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Disease Type
      • 7.4.5.4.3. Market size and forecast, by Therapy Type
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Disease Type
    • 7.5.3. Market size and forecast, by Therapy Type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Disease Type
      • 7.5.5.1.3. Market size and forecast, by Therapy Type
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Middle East And Africa
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Disease Type
      • 7.5.5.2.3. Market size and forecast, by Therapy Type
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Lupin
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Macleods Pharmaceuticals Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
  • 9.3. Sanofi
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Otsuka Pharmaceutical Co., Ltd.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Key strategic moves and developments
  • 9.5. Pfizer Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. FRESENIUS SE & Co. KGaA (Fresenius Kabi)
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Johnson & Johnson
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Teva Pharmaceutical Industries Ltd.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Novartis AG
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. ANI Pharmaceuticals, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments